Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTH Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

CRF - Nociceptin Receptor Interactions

NCT03302416
View directory record Official record
Conditions
Healthy
Interventions
Hydrocortisone, [C-11]NOP-1A
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 19, 2026, 2:37 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Epidural Analgesia, Beta-Endorphin Concentrations in Colostrum, and Infant Neurobehavior as Breast-Feeding Predictors

NCT01191970
View directory record Official record
Conditions
Breastfeeding, Lactation, Analgesia
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 19, 2026, 2:37 PM EDT
Not listed Not applicable Interventional

Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses

NCT01900093
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Aaron Miller
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 19, 2026, 2:37 PM EDT
Withdrawn Phase 2 Interventional

Androgen Reduction in Congenital Adrenal Hyperplasia

NCT03548246
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Abiraterone acetate, Placebo, Hydrocortisone, Fludrocortisone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 9 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 19, 2026, 2:37 PM EDT
Not listed Phase 3 Interventional

The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis

NCT03511625
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Acthar Injectable Product, Depo medrol
Drug
Lead sponsor
Attune Health Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 19, 2026, 2:37 PM EDT
Recruiting No phase listed Observational

Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma

NCT06344143
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS)
Interventions
Various labs and imaging tests
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 19, 2026, 2:37 PM EDT
Completed No phase listed Observational

Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome

NCT00001453
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 19, 2026, 2:37 PM EDT
Completed No phase listed Observational

Study of Cushing's Syndrome Not Related to ACTH Production

NCT00006278
View directory record Official record
Conditions
Cushing's Syndrome, Healthy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 2:37 PM EDT
Completed No phase listed Observational

Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis

NCT04642391
View directory record Official record
Conditions
Cirrhosis, Adrenal Insufficiency
Interventions
Cosyntropin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 100 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 19, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
View directory record Official record
Conditions
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
Interventions
Pasireotide, Cabergoline, Pasireotide LAR
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 19, 2026, 2:37 PM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

NCT02486744
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Acthar Gel
Drug
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 19, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

NCT01374906
View directory record Official record
Conditions
Cushing's Disease
Interventions
pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 19, 2026, 2:37 PM EDT
Withdrawn Phase 2 Interventional

Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease

NCT04339751
View directory record Official record
Conditions
Cushing's Disease
Interventions
Vorinostat
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 19, 2026, 2:37 PM EDT
Completed Not applicable Interventional

Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock

NCT00005890
View directory record Official record
Conditions
Septic Shock
Interventions
corticotropin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
1 Month to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy

NCT03400852
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
MNK-1411, Placebo
Drug · Other
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
4 Years to 8 Years · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Gulf Breeze, Florida • Atlanta, Georgia • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 19, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

ACTH in Progressive Forms of MS

NCT01950234
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
ACTH, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Fargo, North Dakota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 19, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

NCT04169061
View directory record Official record
Conditions
Keratitis
Interventions
Acthar
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 19, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

NCT02697734
View directory record Official record
Conditions
Cushing's Disease
Interventions
osilodrostat, osilodrostat Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 19, 2026, 2:37 PM EDT
Terminated Phase 4 Interventional Results available

Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar

NCT02546492
View directory record Official record
Conditions
Transplant Glomerulopathy
Interventions
Acthar gel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 19, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 19, 2026, 2:37 PM EDT
Not listed No phase listed Observational

Dermatomyositis and Polymyositis Registry

NCT01637064
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Acthar
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
5
States / cities
Phoenix, Arizona • San Diego, California • Columbia, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 19, 2026, 2:37 PM EDT
Suspended No phase listed Observational

Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome

NCT03042637
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
Acthar Gel and Tacrolimus
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 19, 2026, 2:37 PM EDT
Not listed Early Phase 1 Interventional

Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

NCT01422746
View directory record Official record
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 19, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?

NCT00208897
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Fluoxetine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 19, 2026, 2:37 PM EDT